Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PLA2G7 | Q13093 | 17/20 | 0.68 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | AHR | P35869 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263893 | 0.82 | KDM4E (0.69) | KDM4ETDP1PLA2G7GPR35MEN1 | |
| SCHEMBL1759095 | 0.82 | KDM4E (0.69) | KDM4ETDP1PLA2G7GPR35MEN1 | |
| SCHEMBL11810085 | 0.80 | GPR35 (0.70) | KDM4ETDP1PLA2G7GPR35MEN1 | |
| SCHEMBL30054313 | 0.78 | GAA (0.77) | KDM4ETDP1PLA2G7GPR35MEN1 | |
| SCHEMBL2004648 | 0.77 | KDM4E (0.63) | KDM4ETDP1PLA2G7GPR35MEN1 | |
| SCHEMBL14665026 | 0.75 | KDM4E (0.59) | KDM4ETDP1PLA2G7GPR35MEN1 | |
| Transtorine SCHEMBL29366068 | 0.74 | KDM4E (1.00) | KDM4ETDP1GPR35MEN1GRIN2D | |
| Transtorine SCHEMBL5144405 | 0.74 | KDM4E (1.00) | KDM4ETDP1GPR35MEN1GRIN2D | |
| SCHEMBL31672966 | 0.73 | KDM4E (0.69) | KDM4ETDP1PLA2G7GRIN2DALDH1A1 | |
| SCHEMBL9452250 | 0.73 | KDM4E (0.58) | KDM4ETDP1GPR35MEN1GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025107568-A1 | USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR | 集美大学 | 2025-05-30 | — | — | WO | claimed |
| CN-115711954-B | Urine biomarker combination for diagnosing juvenile depression and application thereof | 重庆医科大学 | 2024-07-23 | — | — | CN | claimed |
| WO-2024109768-A1 | ALZHEIMER'S DISEASE MARKER BASED ON BLOOD METABOLITE AND USE THEREOF | 中国科学院深圳先进技术研究院 | 2024-05-30 | — | — | WO | claimed |
| WO-2022210606-A1 | METHOD FOR EVALUATING FUTURE RISK OF DEVELOPING DEMENTIA | 味の素株式会社 | 2022-10-06 | — | — | WO | claimed |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | NEUSCO BIOTECH LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4174070-B1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NEUSCO BIOTECH LTD (CN) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025107568-A1 | USE OF KYNURENIC ACID IN RESISTING HYPERURICEMIA AND STRUCTURAL ANALOG THEREOF IN PREPARING XOD INHIBITOR | 集美大学 | 2025-05-30 | — | — | WO | disclosed |
| CN-119677529-A | Kynurenine aminotransferase and products thereof for the treatment of arthritic diseases | 法国国家农业食品与环境研究院 | 2025-03-21 | — | — | CN | disclosed |
| CN-118488849-A | Kynurenine aminotransferase and products thereof for the treatment of inflammatory bowel disease | 法国国家农业食品与环境研究院 | 2024-08-13 | — | — | CN | disclosed |
| CN-115711954-B | Urine biomarker combination for diagnosing juvenile depression and application thereof | 重庆医科大学 | 2024-07-23 | — | — | CN | disclosed |
| CN-115711954-B | Urine biomarker combination for diagnosing juvenile depression and application thereof | 重庆医科大学 | 2024-07-23 | — | — | CN | disclosed |
| US-20240226085-A1 | KYNRENINE AND DERIVATIVES THEREOF FOR TREATING ATROPHIC SCARRING | BIRCHBIOMED INC. (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20100092999-A1 | XANTHURENIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITIONS AND METHODS RELATED THERETO | NATURON, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20060089380-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LTD. (AU) | 2006-04-27 | — | — | US | disclosed |
| US-5652093-A | Analogues of reporter groups as background reducers in binding assays | APROGENEX, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| US-5501952-A | Analogues of reporter groups as background reducers in hybridization assays | APROGENEX, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1995002699-A1 | ANALOGUES OF REPORTER GROUPS AS BACKGROUNG REDUCERS IN HYBRIDIZATION ASSAYS | APROGENEX, INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| US-5312922-A | Quinoline derivatives with hydroxy, trifluoromethyl, carboxy and/or bromo substituents | NORDION INTERNATIONAL INC. (CA) | 1994-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PARK7, COQ8A, NLN | KDM4E 3604/4885TDP1 888/4885PLA2G7 2171/4885 |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | LPAR1, PLA2R1, LPAR2 | KDM4E 4345/4885TDP1 515/4885PLA2G7 20/4885 |
| US-20060089380-A1 | 8-Hydroxy quinoline derivatives | PARK7, HTT, SNCA | KDM4E 2123/4885TDP1 193/4885PLA2G7 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.